Literature DB >> 10725266

Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats.

S M Gardiner1, T R Auton, M R Downham, H L Sharp, P A Kemp, J E March, H Martin, P J Morgan, A Rushton, T Bennett, J F Glover.   

Abstract

1. Male, Sprague-Dawley rats were actively immunized with novel angiotensin vaccines, and their pressor responses to exogenous angiotensin I (AI) and angiotensin II (AII) were assessed in vivo. Serum antibody titres were also measured. 2. The most effective vaccine consisted of an AI analogue conjugated with a tetanus toxoid carrier protein and adjuvanted with aluminium hydroxide. When this vaccine was injected on days 0, 21 and 42, pressor responses to AI on day 63 were significantly inhibited (maximum, 8.9 fold shift), but responses to AII were unaffected. The anti-angiotensin antibody titre was increased 32,100 fold, and, uniquely, these antibodies also cross-reacted with angiotensinogen. 3. These findings indicate that active immunization against AI may be a useful approach for treating cardiovascular disorders involving the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725266      PMCID: PMC1571954          DOI: 10.1038/sj.bjp.0703178

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

Review 1.  The renin-angiotensin system and its receptors.

Authors:  U Stroth; T Unger
Journal:  J Cardiovasc Pharmacol       Date:  1999       Impact factor: 3.105

Review 2.  Immunologic approaches to blockade of the renin-angiotensin system: a review.

Authors:  J B Michel; C Guettier; R Reade; S Sayah; P Corvol; J Ménard
Journal:  Am Heart J       Date:  1989-03       Impact factor: 4.749

3.  Differential effects of endotoxaemia on pressor and vasoconstrictor actions of angiotensin II and arginine vasopressin in conscious rats.

Authors:  S B Tarpey; T Bennett; M D Randall; S M Gardiner
Journal:  Br J Pharmacol       Date:  1998-04       Impact factor: 8.739

Review 4.  Angiotensin-converting enzyme inhibitors.

Authors:  N J Brown; D E Vaughan
Journal:  Circulation       Date:  1998-04-14       Impact factor: 29.690

5.  Biological significance of renin angiotensin immunization.

Authors:  C I Johnston; J S Hutchinson; F A Mendelsohn
Journal:  Circ Res       Date:  1970-10       Impact factor: 17.367

6.  Non-angiotensin effects of angiotensin-converting enzyme inhibitors.

Authors:  W Sunman; P S Sever
Journal:  Clin Sci (Lond)       Date:  1993-12       Impact factor: 6.124

Review 7.  Recent progress in angiotensin II type 2 receptor research in the cardiovascular system.

Authors:  M Horiuchi; M Akishita; V J Dzau
Journal:  Hypertension       Date:  1999-02       Impact factor: 10.190

Review 8.  Angiotensin II receptor inhibition. A new therapeutic principle.

Authors:  F H Messerli; M A Weber; H R Brunner
Journal:  Arch Intern Med       Date:  1996-09-23

9.  Lack of effect of TNF antibodies on the cardiovascular sequelae of lipopolysaccharide infusion in conscious rats.

Authors:  J Waller; S M Gardiner; J Jose; T Bennett
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Renal hypertension in rats immunized against angiotensin I and angiotensin II.

Authors:  H F Oates; G S Stokes; B G Storey; R G Glover; B F Snow
Journal:  J Exp Med       Date:  1974-02-01       Impact factor: 14.307

  10 in total
  13 in total

1.  Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease.

Authors:  Atul J Butte; Tara K Sigdel; Persis P Wadia; David B Miklos; Minnie M Sarwal
Journal:  Mol Cell Proteomics       Date:  2010-12-23       Impact factor: 5.911

Review 2.  Therapeutic potential of vaccines in the management of hypertension.

Authors:  Morris J Brown
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Success and failure of vaccines against renin-angiotensin system components.

Authors:  Morris J Brown
Journal:  Nat Rev Cardiol       Date:  2009-08-25       Impact factor: 32.419

4.  Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.

Authors:  M R Downham; T R Auton; A Rosul; H L Sharp; L Sjöström; A Rushton; J P Richards; T G K Mant; S M Gardiner; T Bennett; J F Glover
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 5.  Hypertension Vaccine may be a boon to millions in developing world.

Authors:  Mohan Bairwa; Manju Pilania; Vivek Gupta; Kapil Yadav
Journal:  Hum Vaccin Immunother       Date:  2013-12-23       Impact factor: 3.452

6.  Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice.

Authors:  Futoshi Nakagami; Hiroshi Koriyama; Hironori Nakagami; Mariana Kiomy Osako; Munehisa Shimamura; Mariko Kyutoku; Takashi Miyake; Tomohiro Katsuya; Hiromi Rakugi; Ryuichi Morishita
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

7.  Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a).

Authors:  Mariko Kyutoku; Hironori Nakagami; Hiroshi Koriyama; Futoshi Nakagami; Munehisa Shimamura; Hitomi Kurinami; Hideki Tomioka; Takashi Miyake; Tomohiro Katsuya; Ryuichi Morishita
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

8.  Effect of active immunization against angiotensin II type 1 (AT1) receptor on hypertension & arterial remodelling in spontaneously hypertensive rats (SHR).

Authors:  Liu-Dong Li; Miao Tian; Yu-Hua Liao; Zi-Hua Zhou; Fen Wei; Feng Zhu; Min Wang; Bin Wang; Yu-Miao Wei
Journal:  Indian J Med Res       Date:  2014-04       Impact factor: 2.375

Review 9.  Therapeutic Vaccines for Hypertension: a New Option for Clinical Practice.

Authors:  Hironori Nakagami; Ryuichi Morishita
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 4.592

Review 10.  Peptide Vaccines for Hypertension and Diabetes Mellitus.

Authors:  Hironori Nakagami; Hiroshi Koriyama; Ryuichi Morishita
Journal:  Vaccines (Basel)       Date:  2014-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.